BiotechTube
Dermama Bioteknologi Laboratorium

Dermama Bioteknologi Laboratorium

Seoul, South Korea· Est.
dermama.co.id
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Founded in 2006 by dermatologist Dr. Indah Julianto SpKK and incorporated in 2012, DBL is a pioneer in regenerative healthcare in Indonesia. The company holds ISO 9001:2015 certification and a stem cell processing license from the Ministry of Health, offering products such as EXOMETA and EXOPEDI to address dermatological needs. DBL aims to provide better solutions for chronic diseases and to reduce healthcare burdens through scalable exosome and stem cell innovations.

DermatologyRegenerative Medicine

Technology Platform

Exosome isolation and engineering, stem cell processing, and nanoparticle tracking analysis for regenerative therapies.

Opportunities

Expanding exosome-based skincare and therapeutics across Asia’s booming aesthetics market; leveraging the only nationally licensed stem cell lab in Indonesia for CRO/CMO services; platform extension into chronic inflammatory, autoimmune, or degenerative diseases.

Risk Factors

Highly competitive exosome sector with large international players; regulatory complexity and high costs of IND development; heavy reliance on a single founder may limit strategic flexibility and operational scalability.

Competitive Landscape

Competes with ExoCoBio, Direct Biologics, Kimera Labs, and local dermocosmetics. Differentiation stems from Ministry of Health stem cell processing license, clinical dermatology expertise, and a dual model of in-house therapeutics plus fee-for-service.

More companies in South Korea →